Fig. 5From: Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic populationPost-mortem casesCAA, cerebral amyloid angiopathy; PSEN, presenilin; AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration; CBD, corticobasal degenerationBack to article page